Imperial College London

Dr David Pitcher

Central FacultyEnterprise

Imperial College Advanced Hackspace Fellow
 
 
 
//

Contact

 

d.pitcher

 
 
//

Location

 

123Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rotolo:2018:10.1016/j.ccell.2018.08.017,
author = {Rotolo, A and Caputo, VS and Holubova, M and Baxan, N and Dubois, O and Chaudhry, MS and Xiao, X and Goudevenou, K and Pitcher, DS and Petevi, K and Kachramanoglou, C and Iles, S and Naresh, K and Maher, J and Karadimitris, A},
doi = {10.1016/j.ccell.2018.08.017},
journal = {Cancer Cell},
pages = {596--610},
title = {Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting},
url = {http://dx.doi.org/10.1016/j.ccell.2018.08.017},
volume = {34},
year = {2018}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19+ chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.
AU - Rotolo,A
AU - Caputo,VS
AU - Holubova,M
AU - Baxan,N
AU - Dubois,O
AU - Chaudhry,MS
AU - Xiao,X
AU - Goudevenou,K
AU - Pitcher,DS
AU - Petevi,K
AU - Kachramanoglou,C
AU - Iles,S
AU - Naresh,K
AU - Maher,J
AU - Karadimitris,A
DO - 10.1016/j.ccell.2018.08.017
EP - 610
PY - 2018///
SN - 1535-6108
SP - 596
TI - Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting
T2 - Cancer Cell
UR - http://dx.doi.org/10.1016/j.ccell.2018.08.017
UR - http://hdl.handle.net/10044/1/63970
VL - 34
ER -